

MICHAEL CHURCHILL, PH.D.

BIOTECHNOLOGY EXECUTIVE | COMPANY BUILDER | SCIENTIFIC FOUNDER

Cambridge, MA | michael@attenuated.tech | linkedin.com/in/michael-churchill | attenuated.tech

EXECUTIVE PROFILE

Biotechnology executive, company builder, and scientific founder with experience translating scientific innovation into companies, clinical programs, regulated diagnostics, and scalable organizations. Connects science, strategy, technology, and execution across company formation, precision medicine, translational development, commercialization, and strategic operations.

CORE EXPERTISE

Executive Leadership | Company Building | Strategic Operations | Translational Strategy | Precision Medicine | Clinical Development | Commercialization | IP Strategy and Licensing | Cross-functional Execution | Financing Readiness | AI-enabled Strategy

PROFESSIONAL EXPERIENCE

Founder & Principal - Attenuated Technologies

January 2025 - Present | Remote

Independent biotechnology operating practice for selected executive appointments, strategic engagements, and company-building work.

- Established Attenuated as the operating platform connecting executive leadership, company building, translational strategy, and selected advisory work.
- Serves as Interim CSO/CBO to MultiOmics, leading scientific development, operations, and corporate strategy for an AI-native precision-diagnostics company focused on early breast-cancer detection.
- Created the application and pitch materials supporting MultiOmics' selection into the 2025 C10/LabCentral AI-BioHub cohort.

Senior Director, Translational Science - CREATE Medicines (formerly Myeloid Therapeutics)

May 2023 - January 2025 | Cambridge, MA

Translational leadership and first-in-human clinical execution.

- Led biomarker strategy and translational execution for first-in-human in vivo CAR Phase I program MT302, supporting full enrollment in under 12 months.
- Directed cross-functional startup of multinational Phase I liver-cancer program MT303, expanding the clinical pipeline and international operating footprint.
- Partnered across research, clinical development, regulatory affairs, clinical operations, manufacturing, bioanalytics, and external collaborators to execute integrated clinical strategies.

Founder & Chief Scientist - Brahma Therapeutics

March 2021 - May 2023 | Cambridge, MA

Founder-led platform formation and strategic readiness.

- Negotiated and in-licensed foundational technologies from multiple universities, establishing the scientific and commercial foundation for the company.
- Built a de novo peptide-engineering platform from concept through proof of concept and established laboratory and CMC capabilities supporting development readiness.
- Generated translational evidence that reduced platform risk and strengthened strategic readiness.

PROFESSIONAL EXPERIENCE - CONTINUED

Principal Scientist - SEngine Precision Medicine

October 2018 - July 2020 | Seattle, WA

Precision-medicine implementation, physician collaboration, and company development.

- Developed personalized functional drug-testing panels for more than 100 cancer patients.
- Worked with physicians and tumor boards to interpret functional results alongside sequencing, pathology, treatment history, and clinical context.
- Established clinical reporting processes supporting compliance and physician adoption.
- Played a significant supporting role in an approximately \$9 million financing through financial modeling, valuation work, investor diligence materials, and company presentations; the CEO led the financing.

Lead Scientist - SEngine Precision Medicine

August 2016 - October 2018 | Seattle, WA

Translation of a research platform into a regulated clinical product.

- Built the CLIA-certified P.A.R.I.S. functional drug-screening test and developed quality-control systems enabling clinical-grade testing.
- Automated the high-throughput organotypic culture platform using robotics and acoustic liquid handling.
- The precision-medicine business, including the P.A.R.I.S. platform, was later acquired by Tempus in 2023; Michael was not involved in that transaction.

SELECTED CAREER EVIDENCE

- Company formation: foundational technology licensing and platform creation at Brahma Therapeutics.
- Clinical execution: translational leadership across two first-in-human Phase I programs at CREATE Medicines.
- Commercialization: development and clinical implementation of a CLIA-certified precision-oncology test at SEngine.
- Executive strategy: integrated scientific, operating, corporate, and AI strategy through Attenuated and MultiOmics.

EDUCATION

Ph.D., Cellular Biology - Columbia University, 2016

M.Phil., Biological Science - Columbia University, 2013

M.S., Biological Science - Columbia University, 2012

B.S., Brain and Cognitive Science - Massachusetts Institute of Technology, 2006

EXECUTIVE DEVELOPMENT

AI in Pharma and Biotech - MIT Sloan School of Management, 2024